June 27, 2012 08:00 ET

Equity Research on Allergan Inc. and Teva Pharmaceutical Industries Ltd - Generic Releases and Good Times for Drug Manufacturers

NEW YORK, NY--(Marketwire - Jun 27, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Other industry and are offering free analytical research on Allergan Inc. (NYSE: AGN) and Teva Pharmaceutical Industries Limited (NYSE: TEVA). Register with us now to have free access to these research reports. Simply click on the link below.

The drug manufacturers - other industry has been awash in news as of late. Several companies have recently reported their quarterly earnings, while others have been releasing new generic versions of products. Court cases have also been plentiful, and could have serious effects on those involved. Get your free reports on Allergan Inc. and Teva Pharmaceutical Industries Limited at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Allergan Inc. and Teva Pharmaceutical Industries Limited then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.

The industry as a whole is performing well though, as a recovering economy back home and a broad array of products have helped many through the tricky economic times. Allergan Inc. had a solid 1st quarter, as its diluted earnings per share and total product net sales increased over the same period last year. Allergan Inc. report is accessible for free by registering today at

One company that has been releasing a number of new products recently is Teva Pharmaceutical Industries Limited. Teva UK, part of Teva Pharmaceuticals, newly launched Rivastigmine capsules, its generic version of Exelon®, a Novartis drug used among other things for the treatment of Alzheimer's dementia. Teva has also recently launched Olanzapine and Fluoxetine Capsules, a generic equivalent of Symbyax®. Teva Pharmaceutical Industries Limited report is accessible for free by registering today at 

The two Drug Manufacturers - Other stocks research reports are available for free by signing up now on the link below.


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information